ANTITUMOR AGENTS FROM HIGHER PLANTS

描述(调查人员摘要)：本研究项目旨在 新型抗肿瘤药物的分离与结构鉴定 已确认生物活性的高等植物。预先筛选 生物检测是基于疾病导向的对人类肿瘤的细胞毒性。 细胞系：A-549(非小细胞肺癌)、HT-29(结肠癌)和 MCF-7(乳腺癌)。活性物质的分级提纯 成分将通过选定的生物测定进行指导。的结构 新的化合物将通过现代光谱方法被阐明， 包括高场二维核磁共振、固态核磁共振、质量 光谱分析和X射线结晶学。所有活性化合物都将 提交给国家癌症研究所进行进一步的体外人类 肿瘤细胞面板以及体内异种移植的评估。在.期间 在本次调查过程中，继续收集和预先筛选 来自台湾、北美和印度的更多工厂将被运往 以确保新的现役核电站的可靠供应。

DESCRIPTION (Investigator's Abstract): This research project is aimed at the isolation and structural elucidation of novel antitumor agents from higher plants which have confirmed bioactivities. The prescreening bioassays are based on disease-oriented cytotoxicity against human tumor cell lines: A-549 (non-small cell lung cancer), HT-29 (colon cancer), and MCF-7 (breast cancer). Fractionation and purification of active constituents will be directed by selected bioassay. The structures of novel compounds will be elucidated by modern spectroscopic methods, including high field two-dimensional NMR, solid state NMR, mass spectrometry and X-ray crystallography. All active compounds will be submitted to the National Cancer Institute for further in vitro human tumor cell panels as well as in vivo xenograft evaluations. During the course of this investigation, continuing collection and prescreening of additional plants from Taiwan, North America, and India will be carried out to ensure reliable supplies of new active plants.